3090-47-9

Usage

Type of compound

Naphthalene derivative

Occurrence

Environmental samples, byproduct of combustion processes

Health hazard

Mutagen, potentially carcinogenic

Risks

Poses risks to human health and the environment

Research focus

Toxicological and environmental studies

Regulation

Regulated in some jurisdictions due to potential hazards

InChI:InChI=1/C11H10O2/c12-8-3-4-9(13)11-7-2-1-6(5-7)10(8)11/h1-4,6-7,12-13H,5H2

Upstream product

• 51175-59-8 norbornenoquinone 
• 78548-82-0 1α,4α,4aβ,10aα,5β,8β,8aα,9aβ-octahydro-1,4:5,8-dimethanoanthracene-9,10-dione 
• 539-80-0 Tropone 
• 6829-72-7 1,4-dihydro-1,4-methanonaphthalene-5,8-dione 
• 21428-54-6 1,4,4a,6,7,8a-hexahydro-1,4-methano-naphthalene-5,8-dione 
• 542-92-7 cyclopenta-1,3-diene 
• 54353-48-9 1,4,4a,8a-tetrahydro-1,4-methanonaphthalene-5,8-dione 
• 106-51-4 p-benzoquinone 
• 7213-65-2 5,8-diacetoxy-1,4-dihydro-1,4-methylenonaphthalene 

Downstream Products

• 947-58-0 8,11-dimethoxybenzonorbornadiene 
• 102659-46-1 (+/-)-4-nitro-benzoic acid-(3c,5,8-trimethoxy-1,2,3,4-tetrahydro-1r,4c-methano-naphthalen-2t-yl ester) 
• 1560649-05-9 C₄₅H₅₅FN₈O₆ 
• 1560642-34-3 C₃₀H₃₂F₃N₃O₅S 
• 1560642-35-4 C₄₅H₅₂N₆O₄ 
• 1560642-43-4 C₅₀H₅₃N₇O₅ 
• 1560649-09-3 C₅₂H₅₆N₈O₆ 
• 1560642-50-3 C₃₅H₄₄BN₃O₄ 
• 1560642-52-5 C₄₁H₅₀N₆O₄ 
• 1560643-02-8 C₃₀H₃₁F₄N₃O₅S 
• 1560643-05-1 C₃₅H₄₃BFN₃O₄ 
• 1560643-08-4 C₄₁H₄₈F₂N₆O₄ 
• 1560649-18-4 C₄₅H₅₄F₂N₈O₆ 
• 1560643-26-6 C₃₀H₃₀F₅N₃O₅S 

Relevant academic research and scientific papers

Cycloadditions of isobenzofuran to a constrained template bearing neighboring dienophiles

A high yielding synthesis of the pentacyclic diene-dione 1 has enabled investigation of its reactivity as a double dienophile in Diels- Alder [4+2] cycloadditions with isobenzofuran, leading to novel and highly symmetrical three-sided cavitands 3 and 4.

A simple procedure for preparing annulated p-benzoquinones. Improved synthesis of 1,4-dihydro-1,4-methanonaphthalene-5,8-dione

A simple and efficient two-step, one-pot synthesis of substituted 1,4-dihydro-1,4-methanonophthalene-5,8-diones is reported. This synthesis, which utilizes readily available starting materials and inexpensive reagents, can be used to prepare 1a-1c in 70-90% overall yield. This procedure was extended successfully to prepare a more highly complex annulated p-benzoquinone i.e., 8.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.

Unexpected regioselectivity observed in the bromination and epoxidation reactions of p-benzoquinone-fused norbornadiene: An experimental and computational study

The bromination reaction of p-benzoquinone-fused norbornadiene was studied at various temperatures (?78,??50, 0, 25, and 77?°C). At room temperature, the double bonds of the p-benzoquinone units were mainly brominated. The double bond of the norbornene unit also underwent a bromination reaction in a yield of only 2%. However, the reaction at??78?°C resulted in the formation of products derived from the attack of bromine on the norbornene double bond with higher charge density. In contrast to the bromination reaction, the epoxidation reaction of the same compound with m-chloroperbenzoic acid and dimethyldioxirane exclusively resulted in the formation of products derived from the addition to the double bond of norbornadiene. The regioselectivity observed was investigated and the results were supported by theoretical calculations.

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or harmaceutical com ositions thereof in the treatment of HCV infection or he atitis C.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.

The 1:1 and 2:1 adducts of cyclopentadiene with p-benzoquinone

The exo-cis isomer (8) of the well-known endo-cis 1:1 adduct (4) of cyclopentadiene and p-benzoquinone has been obtained by heating the endo-cis-anti-cis-endo 2:1 adduct (13) with p-benzoquinone and also by haeting 4 alone.The exo-cis isomer of the 1:1 adduct (11) of cyclopentadiene and p-toluquinone has also been obtained for the first time.Heating of the 2:1 adduct 13 gives a mixture containing the endo-anti-exo isomer 15, the exo-anti-exo isomer 16, and 13.The structures of these two new isomers are assigned on the basis of (i) spectroscopic comparison with 13 and the known endo-syn-endo and endo-syn-exo isomers, 12 and 14; (ii) spectroscopic comparison of the corresponding tetrahydro compounds; and (iii) the conversion of tetrahydro 15 by oxidation and acetylation to the syn-hydroquinone diacetate 28, which is stereoisomeric with the anti-hydroquinone diacetate 25, prepared by similar treatment of tetrahydro 13,14, and 16.It is proposed that interconversion of the 1:1 adducts occurs via dissociation-recombination, interconversion of the tetrahydro 2:1 adducts occurs via enolization, while interconversion of the 2:1 adducts themselves can occur by both routes.